menu
    • menu

    Company profile for Simris Group

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our vision for Simris is to play the leading role in a future microalgae-based industry producing products, and materials for products, in a drastically more sustainable way than current industry. The original concept for Simris was to extract EPA and DHA Omega-3 from microalgae, the actual source of these essential fatty acids – not fish! By switching to Omega-3 produced by microalgae on dry land, the vision was to relie...
    Our vision for Simris is to play the leading role in a future microalgae-based industry producing products, and materials for products, in a drastically more sustainable way than current industry. The original concept for Simris was to extract EPA and DHA Omega-3 from microalgae, the actual source of these essential fatty acids – not fish! By switching to Omega-3 produced by microalgae on dry land, the vision was to relieve pressure on marine ecosystems by transforming an industry. The fact is that one microalgae or cyanobacteria produces multiple high value compounds.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Simris GroupSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Herrestadsvägen 24A 27650 Hammenhög
    Telephone
    Telephone
    +46 41 444 5050
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://simrisgroup.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Simris Group AB Notified Of Convertible Bonds Conversion
    Simris Group AB Notified Of Convertible Bonds Conversion

    17 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-17/simris-group-ab-publ-receives-notice-of-conversion-of-convertible-bonds

    PHARMIWEB
    17 Dec 2025
    Share Share
    Simris Group AB Initiates Unit Issue, Seeks Share Issue
    Simris Group AB Initiates Unit Issue, Seeks Share Issue

    17 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-17/simris-group-ab-resolves-on-directed-issue-of-units-proposes-that-an-extraordinary-general-meeting-resolves-on-additional-share-issues-and-announces

    PHARMIWEB
    17 Dec 2025
    Share Share
    Simris Group AB Reports Positive Ongoing ADC Study With Nuvisan
    Simris Group AB Reports Positive Ongoing ADC Study With Nuvisan

    06 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-06/simris-group-ab-announces-positive-results-from-ongoing-antibody-drug-conjugate-adc-study-with-nuvisan

    PHARMIWEB
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search